← All programs
Program 01 · Lead · Preclinical

A temporary, off-the-shelf bridge after radiation injury.

UHRP-Bridge · Permanent invisibility · Temporary graft

Radiation injury requires hematopoietic rescue in days — not the weeks a donor search and conventional transplant take. A banked, engineered product can be on the shelf before it is needed.

The need

Existing countermeasures push the marrow that is left.

The approved drugs for hematopoietic acute radiation syndrome work by stimulating a patient's surviving marrow. For patients past that point, there is nothing to stimulate.

UHRP-Bridge is designed to supply marrow function directly — a temporary graft that carries the patient through the aplastic window, then clears once their own marrow recovers.

63,000
potential casualties in a planning scenario, per RITN
Days, not weeks
the window for hematopoietic rescue after high-dose exposure
Government readiness
the buyer is national preparedness (BARDA / ASPR, DoD), not individual patients
The approach

Invisible while it is needed, gone when it is not.

High-level schematic of the UHRP-Bridge concept in radiation injury.
High-level schematic of the UHRP-Bridge concept — engineered donor HSPCs supply marrow function during the aplastic window, with a safety switch to clear the graft as host hematopoiesis returns.
Preclinical survival and body-weight data following total body irradiation.
Preclinical model characterization: survival and body weight after total body irradiation.
Collaboration & path

Developed with HJF / AFRRI.

The radiation-injury collaboration with HJF / AFRRI is active and ongoing, and gives this program the fastest route to in vivo platform proof. The regulatory route is a medical-countermeasure path, to be defined through FDA and agency interaction.

Evidence package
Animal efficacy model · dose, timing and persistence · safety, off-switch and release testing

Regulatory routes shown are planning hypotheses, not approval claims.

Next: SCID & selected IEIs → Request deck